Related Experiment Video

Updated: Apr 28, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of

Qi-Xing Tan1, Qing-Hong Qin1, Bin Lian1

  • 1Breast Surgery Department, Tumor Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

Experimental and Therapeutic Medicine
|June 19, 2014
PubMed

Insights

Sorafenib therapy improves progression-free survival (PFS) and time to progression (TTP) in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). However, it does not improve overall survival (OS) and increases adverse events.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Standard systemic therapy for HER2-negative advanced breast cancer (ABC) remains an unmet need.
  • Sorafenib, an oral multikinase inhibitor, exhibits antiangiogenic and antiproliferative properties relevant to cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of sorafenib in patients with HER2-negative ABC through a meta-analysis.
  • To determine the impact of sorafenib-based therapy on progression-free survival (PFS), time to progression (TTP), overall survival (OS), and overall response rate (ORR).

Main Methods:

  • A meta-analysis of four randomized controlled trials involving 844 patients with HER2-negative ABC.
  • Literature search conducted across major databases (PubMed, EMBASE, Cochrane) using relevant keywords.
  • Extracted data on survival outcomes, response rates, and major adverse events (AEs).

Main Results:

  • Sorafenib-based therapy significantly improved PFS (HR, 0.78; 95% CI, 0.54-1.02) and TTP (HR, 0.74; 95% CI, 0.50-0.97) compared to control therapies.
  • No significant improvement was observed in OS (HR, 0.95; 95% CI, 0.75-1.15) or ORR (RR, 1.19; 95% CI, 1.01-1.39).
  • Increased incidence of grade 3/4 AEs, including hand-foot skin syndrome, anemia, fatigue, rash, and stomatitis, was noted with sorafenib.

Conclusions:

  • Sorafenib-based therapy enhances PFS and TTP in HER2-negative ABC patients.
  • The treatment did not demonstrate significant benefits in OS or ORR.
  • Combination therapy with sorafenib is associated with increased toxicities, often necessitating dose reductions.
Keywords:
advanced breast cancermeta-analysissorafenib

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K